Supply of pharmaceutical products
Original notice title
Bulgaria – Pharmaceutical products – „Доставка на лекарствени продукти за нуждите на МБАЛ - Хасково АД“.
Opportunity Score
Why this score?
Opportunity
0 / 100
Complexity
0 / 100
Risk factors
Restricted procedure — pre-qualification required
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- МНОГОПРОФИЛНА БОЛНИЦА ЗА АКТИВНО ЛЕЧЕНИЕ - ХАСКОВО АД
- Country
- Bulgaria
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Jul 23, 2027
- Estimated value
- BGN 10.9M
AI tender analysis
Tenderwize prepares an AI analysis of this tender based on the TED notice and procurement documents: scope of work, key requirements, eligibility criteria, risks and questions for the buyer. The analysis is generated when the tender is opened.
Award Criteria
Lot 1
Buyer
Location
гр. Хасково, BGR
Website
Buyer profile
Identifier
126529015
Activity
Health
Lots (1)
LOT-0001
„Доставка на лекарствени продукти за нуждите на МБАЛ - Хасково АД“.
„Доставка на лекарствени продукти за нуждите на МБАЛ - Хасково АД“.
BGN 10.9M
Estimated value
Location
Duration
Category
Award Criteria
Award details
Съгласно чл. 70, ал. 2, т. 1 ЗОП икономически най-изгодната оферта във втория етап на ДСП се определя въз основа на критерия "най-ниска цена".
Procurement Details
- Publication date
- 30 Mar 2025
- Languages
- Bulgarian
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 205935-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
0 / 100
Complexity
0 / 100
Risk factors
Restricted procedure — pre-qualification required
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications